anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study was conducted in three phases: (a) pre-test; (b) intervention; and (c) post-test

Pre-test. Using the 'Structured Observation of Students' Participation in Class', each student in both groups was observed four times during different lessons (with a 1-week interval between observations) to establish a baseline for level of participation. All pre-test observations were conducted between the 2nd and 3rd months of the school year, by an occupational therapist with 8 years of experience working with children with developmental delays. The observer was trained in using the 'Structured Observation of Students' Participation in Class' and was not blinded to the schools' assignment (Co-PID or IS). During this period the teachers, who were blinded to the school assignment, were asked to teach in a regular manner without changing the content or design of their lessons. Next, the teachers filled out the School Function Assessment questionnaire for each student. Finally, based on the 'Structured Observation of Students' Participation in Class' scores and teachers' familiarity with the students' function, the occupational therapist and each of the participating teachers jointly filled-out the 'Goal Attainment Scaling' form. Each student had three goals, one for each of the participation skills: Communicating, Choosing and Initiating. Post-test. This phase was conducted during the 9th and 10th months of the school year, and was identical to the pre-testing phase in terms of both process and measures used
Immunogenic compositions and methods for eliciting an immune response against S. epiderrnidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-Ϝ-glutamic acid (such as ϜDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ϜPGA polypeptide. The ϜPGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses ϜPGA from the cap genes. Further, the expression of a ϜPGA polypeptide by the organism can then be altered.
The patients in intervention group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 6 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
Super-enhancers are a class of DNA cis-regulatory elements that can regulate cell identity, cell fate, stem cell pluripotency, and even tumorigenesis. Increasing evidence shows that epigenetic modifications play an important role in the pathogenesis of various types of cancer. However, the current research is far from enough to reveal the complex mechanism behind it. This study found a super-enhancer enriched with abnormally active histone modifications in pancreatic ductal adenocarcinoma (PDAC), called DKK1-super-enhancer (DKK1-SE). The major active component of DKK1-SE is component enhancer e1. Mechanistically, AP1 induces chromatin remodeling in component enhancer e1 and activates the transcriptional activity of DKK1. Moreover, DKK1 was closely related to the malignant clinical features of PDAC. Deletion or knockdown of DKK1-SE significantly inhibited the proliferation, colony formation, motility, migration, and invasion of PDAC cells in vitro, and these phenomena were partly mitigated upon rescuing DKK1 expression. In vivo, DKK1-SE deficiency not only inhibited tumor proliferation but also reduced the complexity of the tumor microenvironment. This study identifies that DKK1-SE drives DKK1 expression by recruiting AP1 transcription factors, exerting oncogenic effects in PDAC, and enhancing the complexity of the tumor microenvironment.
The present invention relates to methods for producing a number of products. Those products include vaccines, clinical laboratory kits and treatment components. The vaccine products cover: vaccines for bacteria, viruses and parasites in humans and animals; and vaccines for the prevention of malignant tumors in patients showing malignant transformation or as a supportive treatment of patients already having a tumor. The clinical laboratory kits covers: diagnostic kits for efficient diagnosis of diseases caused by microorganisms in humans and animals; diagnostic kits for malignant tumors; tissue typing kits for organ transplantation; and monitoring kits for organ rejection and hypersensitivity. The treatment components will help in treatment of difficult disorders including, among others, hypersensitivity disorders, chronic graft rejection, and autoimmune disorders. In effect, the products that can be produced based on this discovery are innumerable. The invention methods are based on our discovery of a new function for RBCs which is their ability to selectively transport self and foreign antigens.
PURPOSE: Approximately 20% to 30% of intracerebral hemorrhage (ICH) patients were reported to be on antiplatelet therapy (APT), and association between prior APT and prognosis was unclear. We aimed to clarify the impact of APT on the prognosis of ICH through an updated systematic review and meta-analysis, and to further compare the risk of single APT (SAPT) or dual APT (DAPT) prior to ICH as well as the risk associated with various antiplatelet drugs.
METHODS: EMBASE, MEDLINE via Ovid SP and Web of Science were searched from inception of each database to November 4, 2023. Included studies reported prognosis in both patients with prior APT and those without.
FINDINGS: A total of 433,103 patients from 43 studies were included in the meta-analysis. Both univariate and multivariate analyses demonstrated a significant association between prior-APT and an increased mortality risk (odd ratio [OR] 1.43, 95% confidence interval [CI] 1.28-1.59; OR 1.20, 95%CI 1.10-1.30, respectively). The risk was higher in short term follow-up (Univariate OR 1.73, 95%CI 1.22-2.46; Multivariate OR 1.94, 95%CI 1.48-2.55). A notably increased risk of hematoma expansion was also observed in patients previously treated with APT (Univariate OR 1.47, 95%CI 1.12-1.94; Multivariate OR 1.88, 95%CI 1.30-2.71), which were mainly attributed to events within 24 hours. The impact of prior-APT on poor functional outcome was inconsistent between univariate and multivariate analyses. Both direct and indirect comparisons showed that SAPT significantly reduced the risk of mortality (OR 0.67, 95%CI 0.64-0.70; OR 0.84, 95%CI 0.71-0.99) and poor functional outcome (OR 0.84, 95%CI 0.72-0.98; OR 0.81, 95%CI 0.72-0.91) compared to DAPT.
IMPLICATIONS: Prior-APT increased the risk of mortality and hematoma expansion in patients with ICH. The increased risk of mortality and hematoma expansion was more obvious in the short term follow-up and within 24 hours, respectively. The effect of APT on poor functional outcome exhibited inconsistency between univariate and multivariate analyses, suggesting that further investigation is warranted to clarify this relationship. In comparison with DAPT, SAPT could decrease the risk of mortality and poor functional outcome. Further studies focusing on antiplatelet drug response, racial differences, and specific APT regimens may help verify the influence.
FIELD: biotechnology, genetic engineering. SUBSTANCE: invention relates to preparing recombinant plasmid DNA pC-NS3 providing integration of complex of genes C, prM, E, NS1, NS 2A, NS 2B, NS 3 of tick-borne encephalitis virus in genome of bovine vaccine virus and the corresponding strain of the latter. Plasmid has also promoter p7, 5K bovine vaccine virus, synthetic DNA-fragments with initiation sites and translation termination and the DNA sequence of thymidine kinase gene of bovine vaccine virus. Obtained plasmid DNA pC-NS3 is used for incorporation of complex of genes C-NS3 of tick-borne encephalitis virus in genome of bovine vaccine virus. Recombinant bovine vaccine virus in cells of immunized organism provides expression of complex of tick-borne encephalitis virus that promotes the formation of protective immunity against infection with tick-borne encephalitis virus. EFFECT: recombinant plasmid preparing. 2 cl, 1 tbl, 1 dwg
Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.
Meibomian gland probing is a relatively new, safe, and effective technique for treating obstructive meibomian gland dysfunction (o-MGD). It involves topical anesthesia of the eyelid margins and insertion of a 2 mm or 4 mm sterile, beveled, solid stainless steel probe at the slit lamp. Meibomian gland probing has been reported to alleviate symptoms (lid tenderness / lid margin congestion) of o-MGD (Maskin, 2010). It has also been shown to improve meibum lipid levels, viscosity, and tear breakup time (Nakayama, Kawashima, Kaido, Arita, \& Tsubota, 2015). Though probing has been investigated in a few small studies of o-MGD, only one small study of 10 participants has investigated meibomian gland probing in ocular rosacea (Wladis, 2012). This study showed improvement in ocular surface disease index (OSDI, a standardized questionnaire assessing dry eye) but did not show objective improvement by way of examination findings or analysis of meibum (Wladis, 2012).

In our study, Investigators intend to further investigate meibomian gland probing in participants with diagnosed ocular rosacea. Investigators hypothesize that after probing of one eye, Investigators will note improvements in participants symptoms as reflected in improvement in OSDI scores, Reductions in Inflamma-Dry measures (measure of matrix metalloproteinase (MMP-9), an inflammatory marker elevated in tears of participants with dry eye), decreased tear fluid osmolarity, decreased meibum viscosity on expression . Objective improvement in lid margin disease (noting collarettes, pitting, telangiectasia of lid margins, thickening / irregularity of lid margins, lid margin tenderness; improvement in tear break up time (TBUT); and improvement in corneal fluorescein / lissamine green staining).
Subjects will receive BTX in the glabella and forehead regions, using a traditional injection technique commonly utilized in aesthetic medicine. The traditional injection technique will deposit the neurotoxin into the targeted muscles; with up to 24 units being injected into the forehead and 20 units in the glabella.
PURPOSE: The objective of this study was to compare the efficacy of a low-cost heat-preserving method in preventing intraoperative hypothermia with that of forced-air warming in a resource-limited setting.
METHODS: In this randomized controlled non-inferiority trial, we recruited children younger than 12 years scheduled for cranial neurosurgery in a large East-African hospital. Patients were block-randomized by age to intraoperative warming measures using Hibler's method (intervention) or warm air (comparator). Hibler's group patients were circumferentially wrapped in transparent plastic sheeting (providing a vapor-trap) over a layer of cotton blankets, then laid on an insulating foam mattress. Warm air group patients were treated with forced-air convection via an underlying Snuggle Warm™ Pediatric Full Body mattress. Allocated warming measures were initiated in the operating theatre and discontinued upon anesthesia emergence. Perioperative temperatures were measured using noninvasive forehead probes (SpotOn™). The primary outcome was incidence of hypothermia (core temperature < 36.0° for longer than 5 min). Our null hypothesis was that Hibler's method is inferior in efficacy to the warm air method by a margin exceeding 20%. Among secondary outcomes were duration of hypothermia as proportion of surgical duration, incidence of postoperative shivering and rescue measure requirements.
RESULTS: We analyzed data for 77 participants (Hibler's = 38; warm air = 39). There was no significant difference between the Hibler's and warm air arms of the study in the primary outcome of incidence of hypothermia (59.0% vs. 60.5% respectively; OR 1.07; 95% CI 0.43-2.65; p = .890). However, the risk difference (1.55%; 95% CI -0.20 to -0.24) exceeded the 0.2 margin and non-inferiority could not be declared. There was considerable need for rescue measures in both groups (71.1 0% vs. 69.2%; OR 1.09; 95% CI 0.41-2.90; p = .861). There was no statistically significant difference between groups for any prespecified secondary outcome.
CONCLUSION: Although perioperative core temperatures were not significantly different, we could not declare an inexpensive heat-preserving method non-inferior to warm air convection in preventing intraoperative hypothermia in children undergoing anesthesia for cranial neurosurgery in a resource-limited setting. The extensive need for rescue measures may have masked important differences.
TRIAL REGISTRATION: US National Institutes of Health Clinicaltrials.gov database (ID no. NCT02975817).
Participants will receive placebo matching to mavorixafor QD orally for 52 weeks in the Randomized Placebo-Controlled Period. Participants who complete the Randomized Placebo-Controlled Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent AC, will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
PURPOSE:A composition containing gamma-linolenic acid-containing fats and oils extracted from molds of Mortierella. CONSTITUTION:A microorganism (e.g., Mortierella isabellina, etc.) belonging to the genus Mortierella, capable of producing lipid having high content of gamma-linolenic acid, is cultivated in a hydrocarbon medium, etc., to give a mold of Mortierella. Fats and oils containing gamma-linolenic acid are extracted from the mold, and a composition for nutritive cosmetic, a composition for the skin or a drug composition containing the fats and oils is obtained. In case of the composition for cosmetic or for the skin, content of the fats and oils of mold is 1-30wt%, and in case of the nutritive composition, content of fats and oils of mold is 1.34-15wt%. The fats and oils of mold are blended with preferably an antioxidant such as tocopherol, etc., so that the fats and oils of mold are advantageously stabilized. In case of the drug composition, the fats and oils are applicable in the shape of capsule for oral administration. The mold itself before extraction of the fats and oils of mold or a deactivated mold can be used advantageously as a pet food, especially a pet food for cats.
The invention relates to a plaster for treating a stuffy nose and a preparation method thereof. The plaster for treating a stuffy nose comprises the following components in parts by weight: 70-150 parts of ginger and 5-12 parts of single-head garlic. The preparation method comprises the following steps of: crashing the drugs; heating and melting a black plaster blank with the same dosage; doping the crashed drugs into the melted black plaster blank; and spreading the mixture on a square cloth of 4cm. The pure natural food plants are used as raw drugs and have no pollution and no any toxic side effects. A clinical research proves that the plaster has quick treatment effect and low treatment cost. The clinical treatment on 55 patients proves that53 patients can blow the noses in three minutes after the plaster is pasted, 2 patients gain no treatment effect after the plaster is pasted, thus the total effective rate is 95 percent.
Compositions for care of the oral cavity comprise 'particles of a water insoluble plastics material with a size of less than 50 microns, which contain absorbed flavouring material. Plastics materials may be polyvinyl chloride, polyethylene, polypropylene, polymethyl methacrylate, or a co-polymer of polyvinyl chloride and polyvinyl alcohol. Flavouring materials may be menthol, peppermint, spearmint (carvone), wintergreen, or anethole, or mixtures thereof. The compositions may be a dentifrice in the form of a liquid, paste, powder, tablets or a solid block, or may constitute a mouthwash other ingredients conventional for such forms "may be present. The compositions are prepared by contacting 'particles of plastics material with .the flavouring agent, if necessary together with a solvent or another flavouring agent capable of being absorbed by the plastics material (e.g. propylene, glycol, glycerine, cineole or spearmint oil), optionally separating the particles from excess flavouring agent and solvent and incorporating them in an oral. composition. The process is preferably effected at elevated, temperature.
INTRODUCTION: Sarcopenia is a global health problem, there are currently several criteria for its diagnosis and the implementation of its own cut-off values for each population is recommended. The objective was to evaluate the handgrip strength (HG) in postmenopausal women from Buenos Aires and establish a cut-off value.
METHODS: A total of 704 women ≥50 years of age were evaluated, who answered a questionnaire on osteoporosis risk and HG was taken. Those with arthritis or pain in the hands were excluded, leaving 678 women for analysis. A subpopulation of 148 healthy women was selected to define the minimum normal value of the HG of our population.
RESULTS: The HG was 20.44 ± 5.19 kg, with a significant decrease in values after 70 years. The HG in the group of healthy women was 22.08 ± 5.13 kg. And the cutoff value of 17.5 kg was established in our population (first quintile). 28.6% of the total population presented decreased HG and reached 53.7% in women >80 years. HG <17.5 kg was associated with a 67% increased risk of falls in the total group of women >50 years.
DISCUSSION: The HG is a simple tool that is easy to implement in clinical practice and is considered the first step for the diagnosis of sarcopenia. The cut-off value of HG <17.5 kg could be used for the evaluation of sarcopenia in women >50 years of Buenos Aires.
Background \& aims: In Taiwan, with the investigators sternization of eating habit and lifestyle, metabolic syndrome and non-alcoholic fatty liver (NAFLD) have become very important health issues. This project will therefore study the histological and clinical data of patients with non-alcoholic fatty liver disease and explore the impact of exercise intervention on the hepatic fatty infiltration of the patients. The research strategy will include (1) combining modern artificial big data collection technology to fully monitor the daily life, sleep and exercise patterns of the participants; (2) improving fatty liver and metabolic syndrome through trial-based exercise intervention; and (3) exploring the changes of sleep patterns and intestinal microflora in patients with metabolic liver disease after exercise intervention.

Materials \& methods: The investigators will first retrospective collect clinical and histologic data of patients with biopsy proven NAFLD. Second, the investigators will establish a non-invasive fatty liver detection and staging platform at National Taiwan University Hospital. The investigators then plan to enroll 100 patients with non-alcoholic fatty liver from NTUH employees. The investigators will collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening. After one year of exercise intervention, the investigators will analyze the effect of exercise on intrahepatic fat (main parameter: 20% reduction in intrahepatic fat; 30% achieved in the exercise intervention group; 5% achieved in the control group) and related metabolic syndrome indicators, and analyze different types of exercise Whether the intervention has different effects, and analyze the improvement of sleep pattern and intestinal microflora after exercise intervention.
A machine learning engine is presented. The disclosed recommendation engine generates an ensemble of trained machine learning models that are trained on known genomic data sets and corresponding known clinical outcome data sets. Each model can be characterized according to its performance metric or other attributes describing the nature of the trained model. The attributes of the models can also relate to one or more potential research projects, possibly including drug response studies, drug or compound research, types of data to collect, or other topics. The potential research projects can be ranked according to the performance or characteristic metrics of models that share common attributes with the potential research projects. Projects having high rankings according to the model metrics are considered as targeting that would likely be most insightful. Fig. 1 Memory Processor (RAM, Flash, SAN, RAID, Etc.) 150 120 Modeling Engine Modeling Engine Software Instructions <- 130 Ensemble of Trained Clinical Outcome Models PredictionModelTemplates (Trained: SVMs, NFM, ANN, Etc.) Predctin Moel empltes145 (Untrained: SVMs, NFM, ANN, Etc.) <- -45 Trained Model Genomic Data Set(s) <----+ Model Characteristic Metrics (WGSs, WESs, RNAseqs, Etc.) 147A Clinical Outcome Data Set(s) O (IC50, G150, Etc.) Trained Model Model Characteristic Metrics Research Projects 147N (Drugs, Data Collection, Etc.) • Prediction Studies • Data to collect Ensemble Metrics • Drugs 149 • Etc. Ranked Potential Research Projects • Ranked by Model Performance Metric(s) • Ranked by Ensemble Metric(s) • Ranked by ModelAccuracy • Ranked by Model Accuracy Gain • Etc. Figure 1